Barclays
GRCE

Barclays’s Grace Therapeutics GRCE Stock Holding History

Barclays’s Portfolio GRCE Stock Details GRCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1
Closed – – 5068
2021
Q2 		$0 Hold
1
– – ﹤0.01% 5116
2021
Q1 		$0 Hold
1
– – ﹤0.01% 5287
2020
Q4 		$0 Hold
1
– – ﹤0.01% 5192
2020
Q3 		$0 Hold
1
– – ﹤0.01% 5654
2020
Q2 		$0 Sell
1
-14
-93% -$408 ﹤0.01% 6361
2020
Q1 		$0 Sell
15
-2,068
-99% -$73.2K ﹤0.01% 6526
2019
Q4 		$245K Buy
+2,083
New +$206K ﹤0.01% 4880

Other funds holding GRCE

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
SIAP
Sterling Investment Advisors (Pennsylvania) Berwyn, Pennsylvania $599M AUM 28.66% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays's GRCE Position: Q3 2021 in Review

Barclays sold out of Grace Therapeutics (GRCE) in Q3 2021, closing a stake of 1 share.

Barclays first reported a position in GRCE in Q4 2019 and held it in 7 quarters. The position peaked at $245K in Q4 2019. 17 funds tracked by Wall St. Rank hold GRCE as of Q3 2021.

  • Barclays reported no remaining Grace Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Barclays sold 1 Grace Therapeutics share in Q3 2021.
  • Barclays first reported a position in Grace Therapeutics in Q4 2019 and held it in 7 quarters.
  • Barclays's Grace Therapeutics position peaked at $245K in Q4 2019.
  • 17 funds tracked by Wall St. Rank held Grace Therapeutics as of Q3 2021.

Based on Barclays's 13F filing for Q3 2021, filed 9 Nov 2021.